Neuer Bericht von Rockwell Automation: 90 % der Life-Sciences-Hersteller stufen digitale Transformation mittlerweile als geschäftsentscheidend ein

Rockwell Automation reports that 90% of life-sciences manufacturers now view digital transformation as business-critical, while 58% have deployed smart-manufacturing technology at scale or in parts of operations. AI/ML (46%), process automation (44%) and cybersecurity (39%) are the top investment priorities, with 64% of current AI users planning to expand adoption within 12 months. The report also highlights material execution risks: only 32% effectively use more than half of collected data, and 54% of organizations experienced at least one cyberattack in the past year.

Analysis

This is not a near-term demand datapoint for ROK; it is vendor-sponsored survey evidence and should not change estimates absent order, backlog, or software-ARR confirmation. The investable implication is that regulated manufacturing is shifting from episodic capex toward recurring spend on validated data layers, plant-network security, and quality workflows. That mix favors vendors with installed-base access and compliant OT integration—ROK, AVEVA/SCHNEIDER (SU.PA), Siemens (SIEGY), and Honeywell (HON)—over point AI providers whose tools lack validation and audit trails.

The bottleneck is data architecture rather than AI-model availability. Over the next 6-18 months, manufacturers unable to normalize plant and quality data will likely divert budgets from experimental AI applications toward integration, MES, historians, and cybersecurity; this creates a second-order tailwind for AspenTech (AZPN), PTC (PTC), and OT-security providers such as Palo Alto Networks (PANW) and Fortinet (FTNT). Conversely, higher cyber spend may crowd out discretionary automation hardware at smaller biopharma and CDMO customers if funding conditions worsen.

Near term, ROK’s multiple is unlikely to rerate on this release alone: life-sciences adoption cycles are long, require validation, and often convert into services/software revenue only after a controls-system project is approved. The 1-3 month catalyst is management quantifying life-sciences software bookings, recurring revenue growth, and margin contribution; a material acceleration would support the thesis that ROK’s mix is improving rather than merely benefiting from a broad automation cycle. Falsification: weak software bookings or guidance indicating customers are piloting rather than deploying at scale would confirm that the spending remains aspirational.

Key Decisions for Investors

• No immediate directional trade in ROK solely on the survey; maintain an alert for the next earnings call on life-sciences orders, software/ARR growth, and backlog conversion. Upgrade only if management identifies a measurable booking acceleration and software mix supports gross-margin expansion.
• For a 6-12 month thematic expression, prefer a basket long ROK / SIEGY / HON against broad industrial automation exposure (XLI): regulated end-market spending should prove more resilient if general industrial capex softens, but size modestly because implementation cycles delay revenue recognition.
• Watch PANW and FTNT for OT-security pipeline commentary over the next two earnings cycles. Initiate only on independently verified industrial/healthcare billings acceleration; survey-reported cyber concern alone is insufficient to underwrite incremental revenue.
• Avoid treating generic AI software vendors as direct beneficiaries. A validated manufacturing deployment requires integration and compliance evidence; if ROK’s software bookings fail to accelerate within two quarters, the likely outcome is longer services cycles rather than an AI-led automation upcycle.